Latest Breaking News On - Clintt allen - Page 1 : vimarsana.com

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

–   FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to support submission of a...

Precigen (PGEN) Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

Precigen Inc. (PGEN) Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for PRGN-2012

Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen (PGEN) Provides Pipeline and Corporate Updates

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. presented pipeline and corporate updates at the 41st Annual J.P. Morgan Healthcare Conference. PRGN-2012 AdenoVerse™ Immunotherapy in RRP. Overview: PRGN-2012 is an investigational... | January 12, 2023

Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs

– Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase complete...

Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs

Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...